Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

  • Awaiting development
  • GID-TA11657
  • Expected publication date: 

Suggested remit: To appraise the clinical and cost effectiveness of Enzalutamide + Radium-223 dichloride with chemotherapy within its marketing
authorisation for treating prostate cancer